Asset Details
Do you wish to reserve the book?
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy
Do you wish to request the book?
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A region-confined PROTAC nanoplatform for spatiotemporally tunable protein degradation and enhanced cancer therapy
2024
Overview
The antitumor performance of PROteolysis-TArgeting Chimeras (PROTACs) is limited by its insufficient tumor specificity and poor pharmacokinetics. These disadvantages are further compounded by tumor heterogeneity, especially the presence of cancer stem-like cells, which drive tumor growth and relapse. Herein, we design a region-confined PROTAC nanoplatform that integrates both reactive oxygen species (ROS)-activatable and hypoxia-responsive PROTAC prodrugs for the precise manipulation of bromodomain and extraterminal protein 4 expression and tumor eradication. These PROTAC nanoparticles selectively accumulate within and penetrate deep into tumors via response to matrix metalloproteinase-2. Photoactivity is then reactivated in response to the acidic intracellular milieu and the PROTAC is discharged due to the ROS generated via photodynamic therapy specifically within the normoxic microenvironment. Moreover, the latent hypoxia-responsive PROTAC prodrug is restored in hypoxic cancer stem-like cells overexpressing nitroreductase. Here, we show the ability of region-confined PROTAC nanoplatform to effectively degrade BRD4 in both normoxic and hypoxic environments, markedly hindering tumor progression in breast and head-neck tumor models.
Antitumor performance of PROteolysis-TArgeting Chimeras (PROTACs) is limited by their targeting ability and retention to tumor sites. Here the authors design the reactive oxygen species (ROS)-activatable and hypoxia-responsive PROTAC nanoparticles with selective penetration into tumors for degradation of BRD4 to suppress breast and head and neck cancer progression.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/51
/ 14/19
/ 140/131
/ 140/58
/ 147/143
/ 38/77
/ 38/91
/ Animals
/ Antineoplastic Agents - chemistry
/ Antineoplastic Agents - pharmacology
/ Breast
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - metabolism
/ Breast Neoplasms - pathology
/ Bromodomain Containing Proteins
/ Cancer
/ Cell Cycle Proteins - metabolism
/ Chimeras
/ Female
/ Humanities and Social Sciences
/ Humans
/ Hypoxia
/ Matrix Metalloproteinase 2 - metabolism
/ Mice
/ Neoplastic Stem Cells - drug effects
/ Neoplastic Stem Cells - metabolism
/ Nuclear Proteins - metabolism
/ Oxygen
/ Prodrugs
/ Proteins
/ Reactive Oxygen Species - metabolism
/ Science
/ Transcription Factors - metabolism
/ Tumor Microenvironment - drug effects
/ Tumors
